Latest Investment News

Emyria has begun treating the first Medibank-funded PTSD patients at its Perth clinic, marking a pioneering step in private insurance coverage for psychedelic-assisted therapy in Australia. This milestone fuels rapid clinic expansion and supports the company’s national rollout strategy.

WhiteHawk Limited appoints Giuseppe Porcelli as Chief Strategy Officer to spearhead international growth and strengthen investor confidence, while progressing key U.S. federal cybersecurity contracts.

SKS Technologies has reported a remarkable near doubling of revenue to $261.7 million in FY25, driven by strong growth in data centre projects and traditional markets. The company’s robust order book and expanded bank facilities position it well for continued growth in FY26.

SKS Technologies has delivered a remarkable 92% revenue surge in FY25, driven by its data centre strategy and traditional business growth, while expanding bank facilities and forecasting $300 million revenue for FY26.

Neurizon Therapeutics reported a $16.6 million loss for FY2025 amid significant progress in its lead neurodegenerative therapy NUZ-001, including regulatory milestones and a global licensing deal. The company is poised to enter a pivotal ALS clinical trial pending FDA clearance.

Lake Resources N.L. has updated its Kachi Phase One DFS Addendum, showcasing improved lithium brine grades, enhanced extraction technology, and stronger project economics, positioning the Kachi lithium project closer to development.

Victory Metals secures $11.5 million through a strategic placement to accelerate drilling and development at its North Stanmore heavy rare earth project, reinforcing its position as Australia’s leading rare earths explorer.

Calix Limited reported a 17% rise in product and services revenue for FY25, driven by its Magnesia and Leilac businesses, alongside a 23% reduction in operating expenses. The company extended its cash runway to 18 months, supported by a $21 million equity raise, while progressing key decarbonisation projects.

Integral Diagnostics (IDX) reported a robust FY25 with 33.7% revenue growth and operating EBITDA margin expansion, driven by the Capitol merger and organic growth. The company exceeded synergy expectations and outlined a confident outlook amid favourable industry tailwinds.

Ingenia Communities Group reported a 9.6% rise in revenue to $517.7 million for FY25, driven by strong home settlements and rental income growth. Underlying profit surged 33% to $126.1 million, while statutory profit soared 816%, reflecting prior year impairments and fair value gains.

Calix Limited reported a $20.1 million loss for FY2025 despite an 11.2% increase in revenue, reflecting ongoing investment in its industrial decarbonisation technology platform.

Integral Diagnostics Limited (ASX – IDX) reported a robust FY25 performance, boosted by its transformative merger with Capitol Health Limited. The company posted strong revenue and profit growth, declared a 4.0 cent final dividend, and outlined strategic priorities including AI adoption and teleradiology expansion.